^
BIOMARKER:

MHC-II expression

MHC-II expression
HL
nivolumab
Sensitive: C3 – Early Trials
MHC-II expression
HER2 Negative Breast Cancer
pembrolizumab + durvalumab
Sensitive: C3 – Early Trials